Skip to main content
. Author manuscript; available in PMC: 2015 Jan 8.
Published in final edited form as: Am J Transplant. 2013 Sep 5;13(11):3021–3030. doi: 10.1111/ajt.12417

Figure 5. Administration of Fc-silent anti-CD154 dAbs results in antigen-specific iTreg conversion.

Figure 5

(A) Representative flow plots of CD25+ Foxp3+ iTreg among antigen-specific Thy1.1+ CD4+ T cells in draining lymph nodes at day 11. (B) Summary data of percentages of CD25+ Foxp3+ cells within the antigen-specific CD4+ T cell compartment. Treatment with MR-1, 7E1-G2b or CD154 dAbs resulted in a significant increase in the percentage of antigen-specific iTregs. (C) Treg:Effector cell ratio for antigen-specific CD4+ and CD8+ T cells in each treatment group. Treatment with MR-1, 7E1-G2b or CD154 dAbs results in a significant increases in the ratio of Tregs to both CD4+ and CD8+ antigen-specific effector cells. Data are cumulative of two separate experiments with a total of eight to nine mice per group. *** p < 0.001.